NASDAQ:VKTX

Viking Therapeutics Stock News

etoro logo Buy VKTX
*Your capital is at risk
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.
Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment that c
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
GLP-1 weight-loss drugs have taken the pharmaceutical world by storm, Novo Nordisk (NVO) and Eli Lilly (LLY) making a name for the class of drugs through their own landmark brands. But what about the
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
Viking Therapeutics has a high valuation for a company with no sales. Novo Nordisk is competing in the same market, and that market is growing rapidly.
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.

3 Unstoppable Stocks to Buy in August

07:45am, Saturday, 03'rd Aug 2024
Novo Nordisk is big but has plenty of room to grow. Vertex Pharmaceuticals' existing products and pipeline programs give it multiple growth catalysts.
The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight l
Easily one of the biggest trends right now in the field of medicine is the weight loss drug surge. Without attempting to sound cynical, the reality is that the sector enjoys a massive total addressabl
Viking Therapeutics has a powerful weight loss candidate in late-stage trials. Zealand Pharma has a handful of programs and a powerful collaborator.
These overlooked breakout stocks may not grab headlines, but they can deliver stellar returns. Investors must diversify their portfolios with lesser-known companies from time to time.
The cost of taking out fresh debt is an important consideration for some biotechs. There's reason to believe that debt financing is about to get a bit cheaper.
The upstart biotech just reported its Q2 earnings -- and investors were pleased. All of its programs are proceeding according to plan, and it isn't spending much.
Artificial intelligence (AI) chip leader Nvidia has soared 126% so far this year -- but this biotech stock has advanced even more. This biotech player is targeting a market that could be worth $100 bi
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE